International Health Research Institute

Applied Research | Unit 01: Bio-Risk & Genomics | IHRI
Bio-Risk and Genomics Research
Applied Research | Unit 01

Global Bio-Risk &
Genomic Surveillance.

Investigating the intersection of genomic surveillance, dual-use technology governance, and pandemic preparedness to generate evidence that strengthens public health response and policy.

Research Focus Areas

Research Focus Areas

Research translating complex multi-omics data and pathogen surveillance into evidence-based guidance for public health and policy networks.

Biorisk Management

Developing protocols to detect, contain, and respond to engineered and naturally occurring biological threats.

Genomics & Omics

Advancing research in transcriptomics, bio-markers, and the metabolic pathways of systemic disease.

Dual-Use Tech

Governance frameworks for biotechnologies that possess both therapeutic and destructive potential.

Pandemic Response

Developing rapid-response strategies for high-consequence biological events and zoonotic spillover.

Unit Leadership

Led by specialist researchers in biological risk, complex genomics, and global public health science.

Pending Appointment

Lab A Lead

Global Bio-Risk & Genomic Surveillance

Dr. Ari Meerson

Dr. Ari Meerson

Lab B Lead

Genomics & Biological Systems

Expert in molecular genomics, Oxford Nanopore sequencing, and microRNA biomarkers for chronic disease.

Regulatory Compliance Note

Unit 01 (Bio-Risk & Genomics) is an independent applied research node operated by the International Health Research Institute (IHRI) under Pillar II (Applied Research). Participation, research alignment, or data-sharing within this unit does not confer academic credit towards the MFHEA-accredited Doctor of Health Science (DHS) programme. For information regarding our formal MQF/EQF Level 8 degree qualifications, please refer to the Doctoral School.

Partner with Unit 01

We invite practitioner-scholars, research organisations, and clinical institutions to explore independent research collaboration in genomic surveillance and biological risk. Enquiries from academic and institutional partners are welcome.